Cresco Labs Earnings + Call Notes
U.S. cannabis leader shares Q124 results
$184.3M Revs; est. $183.3M
$53.1M AEBITDA; est. $47.3M
$92.2M GP; est. $92.8M
$29.2M OI; est. $23.5M
50% GM; est. 50.6%
($2M) NI; est. ($11.2M)
$124.9m cash
$36.5m CFFO; $33.2m FCF
#1 share in IL PA MA
“I want to thank the Cresco team for taking our learnings from the Year-of-the-Core, making them a part of our DNA and producing such a strong start to 2024. The continued development of our teams’ capabilities and our relentless focus on efficient execution is leading to very strong performance across our retail and branded product business resulting in a 10x increase in operating cash flow year-over-year. This is just the start, with upcoming adult use catalysts in Ohio and potential catalysts in Florida and Pennsylvania we have the ability to generate significant operating leverage and additional cash flow going forward.” CEO Charlie Bachtell
Call Notes
Keep reading with a 7-day free trial
Subscribe to Cannabis Confidential to keep reading this post and get 7 days of free access to the full post archives.